EUVIMEDEUVIMED entdecken
Übersichtsarbeit

A Biological Alignment Framework for Interpreting Anti-Inflammatory Cardiovascular Trials in Atherosclerosis

Hua Yan, Dong Yi, Bingyin Wang

aging and disease · 2026

DOI: 10.14336/ad.2026.10405 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift aging and disease, 2026. Verfasst von Hua Yan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Wuhan Asia Heart Hospital, Wuhan University of Science and Technology, Wuhan, China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The inflammatory hypothesis of atherosclerosis has generated large-scale clinical trials with heterogeneous outcomes—from landmark success (CANTOS) to informative neutral results (CIRT). Understanding why anti-inflammatory therapies produce inconsistent outcomes requires a structured translational framework. We conducted a narrative review of randomized controlled trials, Mendelian randomization studies, and mechanistic investigations in anti-inflammatory cardiovascular therapy, searching PubMed, EMBASE, and the Cochrane database through December 2024. Trial outcomes were analyzed through four alignment domains: pathway specificity, target engagement, patient selection, and endpoint matching. Clinical trial outcomes can be systematically characterized by the degree of coherence—or biological alignment—across these four domains. High alignment (CANTOS, Total Alignment Score [TAS] 8/8) is associated with robust clinical benefit; partial alignment (COLCOT, LoDoCo2, TAS 6/8) yields consistent but modest effects; and low alignment (CIRT, TAS 4/8) is associated with neutral results. TAS is calculated as the additive sum of four domain scores (0-8); the "multiplicative" characterization in prior descriptions refers to a conceptual metaphor for rate-limiting failure, not a formal mathematical model. Aging-related processes (inflammaging, immunosenescence, clonal hematopoiesis of indeterminate potential [CHIP]) modify each alignment domain and require explicit incorporation into trial design. The Biological Alignment Model provides a mechanistically grounded, extensible framework for interpreting divergent anti-inflammatory cardiovascular trial outcomes. It enables iterative trial refinement and supports the design of precision immunotherapy strategies in atherosclerosis.

Autor:innen und Institutionen

  • Department of Cardiology, Wuhan Asia Heart Hospital, Wuhan University of Science and Technology, Wuhan, China.

Zitieren

APA

Yan, H., Yi, D., & Wang, B. (2026). A Biological Alignment Framework for Interpreting Anti-Inflammatory Cardiovascular Trials in Atherosclerosis. aging and disease. https://doi.org/10.14336/ad.2026.10405

Vancouver

Yan H, Yi D, Wang B. A Biological Alignment Framework for Interpreting Anti-Inflammatory Cardiovascular Trials in Atherosclerosis. aging and disease. 2026. doi:10.14336/ad.2026.10405

BibTeX
@article{Yan2026,
  author = {Yan, Hua and Yi, Dong and Wang, Bingyin},
  title = {A Biological Alignment Framework for Interpreting Anti-Inflammatory Cardiovascular Trials in Atherosclerosis},
  journal = {aging and disease},
  year = {2026},
  doi = {10.14336/ad.2026.10405}
}
Kostenlos starten →